Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLCAug 20Trial updateRevolution Medicines, Inc.zoldonrasib
Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 resultsAug 11Quarterly updateTango Therapeutics, Inc.
Tango Therapeutics files new $400 million at-the-market equity offering with Leerink PartnersAug 11FinancingTango Therapeutics, Inc.
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Sign inSign in